The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and Janssen’s Stelara) intensify the competition among branded agents, while additional entries and the expanded use of less-expensive biosimilar TNF-α inhibitors provide physicians—and payers—with the potential for more-cost-effective alternatives. The anticipated entry of emerging agents with novel MOAs (e.g., Jak inhibitors) and/or more-convenient delivery formulations (e.g., oral formulations) will further impact the evolving treatment landscape and add greater complexity to market access.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
EU5: France, Germany, Italy, Spain, United Kingdom
Survey of 250
gastroenterologists across the EU5 (50 per country)
Interviews with 10 EU5 payers (2 per country)
KEY DRUGS COVERED
Humira, Remicade, Cimzia, Entyvio, Stelara, biosimilar infliximab, ozanimod, Alofisel, etrolizumab, risankizumab